LA JOLLA, Calif.--(BUSINESS WIRE)--Oct. 26, 2005--Stratagene Corporation (Nasdaq:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostic products, announced today that a settlement has been reached regarding monies due from Abbott Laboratories to Cambridge Antibody Technology (LSE:CAT)(Nasdaq:CATG) (“CAT”) with respect to consideration due on sales of Humira (R). Abbott and CAT collaborated under a research program in the development of Humira (R) for the treatment of rheumatoid arthritis. The first commercial sales of this product occurred in 2003.
